Redding, California - August 9, 2024
Pharmaceutical Contract Development and Manufacturing Market to be Worth $261.57 Billion by 2031
Pharmaceutical Contract Development & Manufacturing Market Size, Share, Forecast, & Trends Analysis by Service (Manufacturing [API, FDF {Parenteral, Injectable, Tablet, Capsule, Oral Liquid, Biologics}], Drug Development) End User - Global Forecast to 2031
Meticulous Research®—a leading global market research company, published a research report titled, 'Pharmaceutical Contract Development & Manufacturing Market Size, Share, Forecast, & Trends Analysis by Service (Manufacturing [API, FDF {Parenteral, Injectable, Tablet, Capsule, Oral Liquid, Biologics}], Drug Development) End User - Global Forecast to 2031.'
The pharmaceutical contract development and manufacturing market is estimated to reach $261.57 billion by 2031 at a CAGR of 7.4% from 2024 to 2031. The growth of this market can be attributed to various factors, such as the pharmaceutical industry's complex manufacturing requirements, manufacturers' growing inclination towards the use of cutting-edge technologies, increasing investments in pharmaceutical R&D, patent expiration, and rising demand for generic medicines and biologics. However, disruption in the supply chain and stringent government regulations are restraining market growth.
Furthermore, growing demand for cell therapies, gene therapies, and personalized medicines and growth in high-potency active pharmaceutical ingredients (HPAPI) and antibody-drug conjugates (ADC) markets are expected to offer growth opportunities. However, intellectual property risks and a need for more skilled professionals are major challenges for market growth.
Key Players
The key players operating in the pharmaceutical contract development and manufacturing market are Lonza Group Ltd. (Switzerland), Catalent Inc. (U.S.), Patheon (Subsidiary of Thermo Fisher Scientific Inc. (U.S.), Recipharm AB (Sweden), C.H. Boehringer Sohn AG & CO. KG. (Germany), Aurobindo Pharma ltd (India), Jubilant Pharmova Limited (India), Fareva SA (Luxembourg), Vetter Pharma International GmbH (Germany), Aenova Group (Germany), WuXi Biologics Inc. (China), Piramal Enterprises Limited (India), Almac Group (U.K.), Fabbrica Italiana Sintetici S.p.A. (F.I.S.) (Italy), Samsung Biologics Co., Ltd (South Korea), Cambrex Corporation (U.S.), Siegfried Holdings AG (Switzerland), FUJIFILM Diosynth Biotechnologies (Japan), and Curia Global, Inc. (U.S.).
Pharmaceutical Contract Development and Manufacturing Market: Future Outlook
The pharmaceutical contract development and manufacturing market is categorized by Type (Pharmaceutical Manufacturing Services [Active Pharmaceutical Ingredient (API) Manufacturing Services and Finished Dosage Forms (FDF) Manufacturing Services {Parenteral/Injectable Manufacturing Services, Tablet Manufacturing Services, Capsule Manufacturing Services, Oral Liquid Manufacturing Services, and Other Formulations}], Drug Development Services, and Biologics Manufacturing Services [Active Pharmaceutical Manufacturing Services (API) Manufacturing Services and Finished Dosage Form Manufacturing (FDF) Services]), End Users (Large Pharmaceutical Companies, Small & Mid-Size Pharmaceutical Companies, and Generic Pharmaceutical Companies), and Geography. The study also evaluates industry competitors and analyzes the market at the global and regional levels.
On the basis of type, the biologics manufacturing services category is estimated to register a higher CAGR of 11.1% during the forecast period. The manufacturing category of biologics is further subdivided into two categories: final dosage form manufacturing (FDF) services and active pharmaceutical manufacturing services (API). In the biologics manufacturing category, a higher CAGR is expected for the FDF category. The increasing significance of biologics and their complex manufacturing processes are the factors for the growth of the FDF manufacturing services category. Finished dosage forms include liquids, semi-solids, injectables, and oral solids. The rise in biologics is the primary cause of the high demand for injectables.
However, the scarcity is being caused by the difficulties involved in the production of biologics. The growth in the market of this category is driven by the rising requirement for contract development of these injectables due to a shortage of manufacturing.
On the basis of end user, in 2024, the large pharmaceutical companies category is expected to account for the largest share of 42.3% of this market. Due to the increasing complexity of drug research and the rising expenses of building and maintaining those facilities, large biotech and pharmaceutical companies are finding it more and more necessary to rely on outside contract manufacturers for help running their intricate operations. Furthermore, because many goods are running out of patents, big pharmaceutical companies rely on manufacturing and contract development firms to release generic versions of these medications onto the market.
This research report analyzes major geographies and provides a comprehensive analysis of the market in North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, Denmark, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, Singapore, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa.
On the basis of geography, in 2024, North America is expected to account for the largest share of 44.3% of this market. This region's large share of the pharmaceutical contract development and manufacturing market is supported by a number of factors, including pipeline diversification, emerging therapies, shifting customer demands, growing demand for biologics and generic drugs, a large number of clinical trials, a large production base of APIs, advanced manufacturing capabilities, and the presence of leading pharmaceutical companies.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5171
Key questions answered in the report-
- Which are the high-growth market segments in terms of type, end user, and region/country?
- What was the historical market size for the pharmaceutical contract development and manufacturing market globally?
- What are the market forecasts and estimates for the period 2024–2031?
- What are the major drivers, restraints, challenges, opportunities, and trends in the pharmaceutical contract development and manufacturing market?
- Who are the major players in the pharmaceutical contract development and manufacturing market?
- What is the competitive landscape like, and who are the market leaders in the pharmaceutical contract development and manufacturing market?
- What are the recent developments in the pharmaceutical contract development and manufacturing market?
- What are the different strategies adopted by the major players in the pharmaceutical contract development and manufacturing market?
- What are the geographical trends and high-growth regions/countries?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
